SCHEMBL5569339

SCHEMBL5569339

CC(O)(c1ccc(NS(=O)(=O)c2ccccc2Cl)cc1)C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 14/20 0.65
PGR P06401 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MCL1 Q07820 1/20 0.53
RORA P35398 1/20 0.53
RORC P51449 1/20 0.53
NR1H2 P55055 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
NR1H3 Q13133 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567757 0.90 HSD11B1 (0.59) HSD11B1PGRALDH1A1RORARORC
SCHEMBL31078033 0.88 RORA (0.68) HSD11B1PGRALDH1A1MCL1RORA
SCHEMBL4597584 0.84 HSD11B1 (0.59) HSD11B1ALDH1A1MCL1RORARORC
SCHEMBL5568555 0.83 MCL1 (0.60) HSD11B1MCL1NR1H2NR1H3
SCHEMBL13852828 0.83 PGR (0.61) HSD11B1PGRALDH1A1MCL1HDAC3
SCHEMBL2901314 0.79 HSD11B1 (1.00) HSD11B1
SCHEMBL2904317 0.79 HSD11B1 (1.00) HSD11B1
SCHEMBL2901310 0.79 HSD11B1 (1.00) HSD11B1
SCHEMBL14613673 0.78 IDH1 (0.61) HSD11B1
SCHEMBL7176420 0.76 PGR (0.65) PGRALDH1A1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076376-B2 Aniline sulfonamide derivatives and their uses AMGEN INC. 2011-12-13 US disclosed
US-8076376-B2 Aniline sulfonamide derivatives and their uses AMGEN INC. 2011-12-13 US disclosed
US-8076376-B2 Aniline sulfonamide derivatives and their uses AMGEN INC. 2011-12-13 US disclosed
WO-2007013929-A1 ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2007-02-01 WO disclosed
US-20070021502-A1 Aniline sulfonamide derivatives and their uses AMGEN INC. 2007-01-25 US disclosed
US-20070021502-A1 Aniline sulfonamide derivatives and their uses AMGEN INC. 2007-01-25 US disclosed
US-20070021502-A1 Aniline sulfonamide derivatives and their uses AMGEN INC. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021502-A1 Aniline sulfonamide derivatives and their uses ARSA, SULT2A1, SULT1A1 HSD11B1 680/4885PGR 2186/4885ALDH1A1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.